<DOC>
	<DOCNO>NCT01353469</DOCNO>
	<brief_summary>Primary Objective : To compare efficacy Insuman Comb 25 versus Novolin速 30R HbA1c reduction 24-week treatment period patient type 2 diabetes mellitus . Secondary Objectives : - To assess effect Insuman Comb 25 versus Novolin速 30R patient type 2 diabetes mellitus fast plasma glucose ( FPG ) - To assess safety tolerability Insuman Comb 25 versus Novolin速 30R patient type 2 diabetes mellitus</brief_summary>
	<brief_title>Assessment Efficacy Safety Insuman Comb 25 Versus Novolin速 30R Twice Daily Over 24 Weeks Type 2 Diabetes Patients With Insulin Therapy</brief_title>
	<detailed_description>The study duration per patient 27 week ( 2 week screen + 24 week open-label treatment + 1 week follow-up ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus patient , define World Health Organization ( WHO ) , diagnose least 1 year time screen visit premix insulin therapy , without oral antidiabetic drug ( OAD ) Signed write informed consent Exclusion criterion : HbA1c &lt; 7 % HbA1c &gt; 10 % screen No selfmonitoring blood glucose within 3 month prior screen visit Premix insulin treatment le 3 month . Insulins premix insulin treatment within 3 month prior screen visit In case treatment OAD , treatment stable OAD dose regimen le 3 month prior screen visit The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>